Mehta Analysis: How Buffett And Friends Can Succeed, And How Pharma Would Be Affected
• By Viren Mehta
How Warren Buffett's company Berkshire Hathaway, Amazon and JPMorgan will address the challenge of creating affordable, quality healthcare for their employees in the US is far from clear, but they are intent on trying. Viren Mehta, founding partner of Mehta Partners LLC, considers what approach they might take to succeed where others have failed, and how such a course would impact on the pharma sector.
Could new partnership finally signal a gear shift in US healthcare machinery? • Source: Shutterstock
“Prices Will Come Down Substantially. Watch.” This is the president of the US talking about drug prices during his State of the Union Message to the US Congress!
The New Year is already full of intrigue, and we're only a few weeks into 2018. The last week of January in particular threw a 1 – 2 – 3...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.
Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.
Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.
Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now
South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.
Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.
